FDA Warning/“Untitled” Letters Will Be Reviewed By Chief Counsel
Executive Summary
Division of Drug Marketing, Advertising & Communications "untitled" letters will be included in a new FDA policy requiring prior approval from the Office of the Chief Counsel before warning letters are issued
You may also be interested in...
FDA’s Office of Chief Counsel Is Growing Its Ranks As It Amends Its Act
Tucked away on the sixth floor of the Parklawn Building in Rockville, FDA's Office of Chief Counsel is calm and quiet. Beneath the surface, however, there is a surge of activity. One of the main engines driving the agency, the 80-lawyer shop helps craft regulations, manages dozens of lawsuits and oversees every enforcement action
FDA’s Office of Chief Counsel Is Growing Its Ranks As It Amends Its Act
Tucked away on the sixth floor of the Parklawn Building in Rockville, FDA's Office of Chief Counsel is calm and quiet. Beneath the surface, however, there is a surge of activity. One of the main engines driving the agency, the 80-lawyer shop helps craft regulations, manages dozens of lawsuits and oversees every enforcement action
FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said